Biopharma · FDA Approvals · Stock

XFOR X4 Pharmaceuticals

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It c…

Assets on file: mavorixafor

Start live analysis of XFOR Run 8-agent AI analysis Stock overview All sector events →

Catalyst calendar

Dated catalysts for XFOR, including recently decided ones.

September 2027

Sep 2027

~ Sep 2027

XFORX4 Pharmaceuticals

mavorixafor: Phase 3 trial NCT06056297 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Recent first-hand events

Every first-hand event for XFOR, newest first.

Instant stream — events appear as soon as they are filed.

Notable

Sep 8, 2026

11:15 AM

XFORX4 Pharmaceuticals

X4 Pharmaceuticals: FDA agrees to 4WARD Phase 3 sample-size reduction

FDA Type C meeting outcome allows reduction of 4WARD Phase 3 enrollment from 176 to 126 participants while preserving statistical power for co-primary endpoints. Company now guides completion of enrollment by year-end 2026 and topline data in H1 2028 to support a future sNDA.

Trial registry changeSEC 8-K